{mosads}”These results demonstrate the cost efficiency of offering this benefit to people who are at high risk of lung cancer,” lead author Bruce Pyenson said in a statement. “The evidence of the value of advanced screening technology for lung cancer has accumulated to the point where we can show very strong cost-effectiveness for the commercial population. We can also jump the needle on cancer mortality for the first time in years, and do so in a cost-effective manner.”
The results confirm research by the National Cancer Institute, which last year published results showing that screening with computed tomography — CT scans — can reduce the risk of dying from lung cancer.